Effect of Thiazolidinedione Treatment Vascular Risk Markers
Information source: University of Arkansas
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Diabetes Mellitus, Type 2; Vascular Diseases
Intervention: Rosiglitazone (Drug); Pioglitazone (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: University of Arkansas Official(s) and/or principal investigator(s): Amy M. Franks, Pharm.D., Principal Investigator, Affiliation: University of Arkansas
Summary
The purpose of this study is to examine the effects of two diabetes medications,
rosiglitazone and pioglitazone, on markers of vascular disease in subjects with type 2
diabetes.
Clinical Details
Official title: A Pilot Study to Determine the Effects of Short-term Thiazolidinedione Treatment on Vascular Risk Markers in Type 2 Diabetes Patients
Study design: Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: determine if treatment with rosiglitazone or pioglitazone affects platelet function as assessed by spontaneous and agonist-induced platelet aggregation
Secondary outcome: adipocytokine concentrations (adiponectin, leptin), hemostatic parameters (fibrinogen, plasminogen activator inhibitor-1), high-sensitivity C-reactive protein
Detailed description:
Diabetes is a common disease in the United States, affecting over 10 million Americans.
Vascular disease, including heart attack and stroke, affects many diabetic patients and will
cause the death of three-fourths of these patients. Because the majority of diabetic
patients will suffer complications or death from vascular disease, we will explore
treatments that have the potential to reduce or prevent vascular disease in type 2 diabetes
patients. Our study will examine the effects of two diabetes medications, rosiglitazone
(ROSI) and pioglitazone (PIO), on markers of vascular disease in 20 subjects with type 2
diabetes. It is thought that these two medications will reduce the risk of vascular disease
by affecting the platelets and proteins that that regulate the processes involved in clot
formation. One-half of the subjects enrolled in our study will take ROSI and the other half
will take PIO. We will measure the clumping ability of these subjects' platelets before,
during, and after three months of treatment with ROSI or PIO. We will measure the blood
concentrations of several proteins (fibrinogen, PAI-1, CRP, adiponectin, and leptin) before
and after treatment with the study drugs. These experiments will give us information about
any beneficial effects of ROSI and PIO on the clot-forming ability in diabetes patients. We
expect that treatment with ROSI and PIO will result in improvement of the disturbed
clot-forming processes that predispose diabetic patients to vascular disease.
Eligibility
Minimum age: 40 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Men and women of all races
- Age 40-65 years
- Diagnosis of type 2 diabetes
- hemoglobin A1C ≥ 7%
- eligible whether or not currently taking antihyperglycemic medications
Exclusion Criteria:
- History of rosiglitazone or pioglitazone use in the previous 3 months
- Known diagnosis of peripheral vascular disease or cardiac failure
- Recent history (within past 6 months) of ischemic stroke, myocardial infarction,
percutaneous coronary intervention, or coronary artery bypass surgery
- Active liver disease or elevated serum transaminases (ALT >2. 5x upper limit of
normal)
- Current therapy with oral anticoagulants (warfarin, heparin, low molecular weight
heparin), clopidogrel, or immunosuppressive agents
- Pregnancy or breastfeeding
- Any other condition, in the opinion of the investigator, that renders the subject
unable to complete the study, that interferes with optimal participation in the
study, or that produces significant risk to the subject
Locations and Contacts
University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States
Additional Information
Starting date: May 2004
Last updated: December 8, 2009
|